Sarda Proteins Falls to 52-Week Low of Rs.59.95 Amidst Market Pressures

Stock Price Movement and Market Context

On 21 Nov 2025, Sarda Proteins opened with a gap down of 4.93%, setting the tone for a challenging trading session. Despite an intraday high of Rs.65, the stock retreated to its lowest point at Rs.59.95, closing near this 52-week trough. This price level represents a substantial drop from its 52-week high of Rs.137.45, reflecting a near 56.4% decline over the past year.

In comparison, the Sensex index opened lower at 85,347.40, down by 285.28 points or 0.33%, and was trading at 85,420.15 during the session, remaining 0.45% below its own 52-week high of 85,801.70. The broader market's relative stability contrasts with the sharper decline seen in Sarda Proteins’ share price.

The stock outperformed its sector on the day by 3.41%, despite the overall negative price movement, indicating some resilience relative to peers within the edible oil industry. However, the stock did not trade on one of the last 20 trading days, suggesting intermittent liquidity or trading interest issues.

Technical Indicators and Trading Patterns

From a technical standpoint, Sarda Proteins’ current price is positioned below its short- and medium-term moving averages, including the 5-day, 20-day, 50-day, and 100-day averages. However, it remains above the 200-day moving average, indicating a complex technical picture where longer-term support levels may still be intact despite recent weakness.

The intraday volatility, with a high of Rs.65 and a low of Rs.59.95, underscores the erratic trading behaviour observed in recent weeks. This volatility may reflect uncertainty among market participants regarding the company’s near-term prospects.

Financial Performance and Fundamental Concerns

Over the last twelve months, Sarda Proteins has recorded a total return of -39.73%, a stark contrast to the Sensex’s positive return of 10.68% over the same period. This divergence highlights the stock’s underperformance relative to the broader market.

The company’s financial disclosures reveal several areas of concern. Notably, Sarda Proteins has not declared results in the past six months, which limits transparency for investors and analysts. The company’s ability to service its debt appears constrained, with an average EBIT to interest ratio of 0.01, indicating minimal earnings before interest and taxes relative to interest obligations.

Additionally, the company has reported losses, resulting in a negative return on equity (ROE). The earnings before interest, taxes, depreciation, and amortisation (EBITDA) have also been negative, signalling operational strain. Profitability has shown a decline of 5% over the past year, further underscoring the challenges faced.

These financial metrics contribute to the stock’s classification as risky when compared to its historical valuation averages. The company’s performance has lagged behind the BSE500 index over one year, three years, and the most recent three months, indicating persistent underperformance across multiple time horizons.

Sector and Industry Positioning

Sarda Proteins operates within the edible oil sector, a segment that has experienced varied performance amid fluctuating commodity prices and changing demand patterns. While the sector itself has shown some resilience, Sarda Proteins’ stock has not mirrored this trend, reflecting company-specific difficulties.

The stock’s erratic trading and recent price lows may also be influenced by broader market sentiment and sector rotation, as investors weigh the outlook for edible oil producers amid global supply chain and pricing dynamics.

Recent Sales Growth Amidst Challenges

Despite the subdued stock performance, Sarda Proteins reported a notable increase in net sales for the half-year ended June 2025. Net sales reached ₹109.55 million, reflecting a growth rate of 18,127.29%. This surge in sales revenue contrasts with the company’s profitability and valuation challenges, suggesting that while top-line growth has been significant, it has not yet translated into improved earnings or market confidence.

This disparity between sales growth and profitability metrics may be a factor contributing to the stock’s current valuation and price behaviour.

Summary of Key Price and Market Metrics

The stock’s 52-week low of Rs.59.95 was recorded today, with an intraday price range between Rs.59.95 and Rs.65. The 52-week high stands at Rs.137.45, illustrating the extent of the stock’s price movement over the past year. The stock’s market capitalisation grade is rated at 3, indicating a mid-tier market cap classification.

Trading activity has been somewhat irregular, with the stock not trading on one of the last 20 days, and showing a day change of 3.08% during the session. The Sensex’s performance remains relatively stable, trading above its 50-day moving average and maintaining a bullish technical stance, which contrasts with the stock’s weaker trend.

Conclusion

Sarda Proteins’ fall to a 52-week low of Rs.59.95 reflects a combination of subdued financial performance, weak debt servicing capacity, and negative profitability indicators. While the company has demonstrated strong sales growth in recent months, this has not yet alleviated concerns around earnings and valuation. The stock’s technical positioning below key moving averages and erratic trading patterns further illustrate the challenges faced in regaining investor confidence.

As the edible oil sector continues to navigate market dynamics, Sarda Proteins remains under close observation for any shifts in its financial disclosures and market behaviour.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →